Navigation Links
PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:12/4/2009

ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is presenting results of a study demonstrating the effectiveness of Valortim® in an inhalation anthrax model in the New Zealand White (NZW) rabbit. The data are being presented during an oral session at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 / BARDA Industry Day being held in Washington, D.C., December 2-4, 2009.

"PharmAthene continues to advance its anthrax pipeline and work collaboratively with the U.S. Government to develop novel vaccines and therapies to address this potentially serious terrorist threat, which has a lethality rate approaching 100% in untreated individuals," commented David P. Wright, President and Chief Executive Officer. "Accumulating evidence suggests that our product, Valortim®, possesses important characteristics that may make it a strong choice for procurement in the Strategic National Stockpile for civilian biodefense, including: demonstrated efficacy in animal models as both a prophylactic and therapeutic for inhalational anthrax; the potential for direct and indirect killing of Bacillus anthracis, a mechanism of action not previously described for other monoclonal antibodies; and, efficacy at low doses."

Summary of Data Presented

In an oral presentation entitled, "Efficacy of Valortim® in the New Zealand White Rabbit Model for Inhalation Anthrax" Dr. Elizabeth Leffel, Director of Non-Clinical Sciences at PharmAthene presented the results from two separate studies where NZW rabbits were challenged with a targeted aerosolized dose of 200 times the median lethal d
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
3. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
7. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
8. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
9. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
10. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
11. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 The Parenteral Drug Association is ... Board of Professional Engineers and Land Surveyors ... to professional engineers for continuing professional competency (CPC) credits. ... value and quality of PDA,s professional education offerings," said ... and hands-on professional training at the Training and Research ...
(Date:6/29/2015)... , June 29, 2015  VisionCare Ophthalmic ... visual prosthetic devices for the treatment of ... publication of "Long-Term (60-month) Results for the ... Stratified by Age in Patients with End-Stage ... . The 5-year data show substantial retention ...
(Date:6/29/2015)... June 29, 2015 Dermatological drugs ... revenues ,Where is the market for dermatological drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 310 page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8
... at the 2011 Pharmaceutical Care Management Association (PCMA),s ... President and CEO Eric Elliott speak about the ... managers as health care reform is implemented, industry ... the market and the pipeline of new treatments ...
... DALLAS, Feb. 8, 2011 ... known for its expertise in understanding consumer data, translating ... effective creative with measurable results, today announced that Peter ... Strategy - Healthcare.  Dannenfelser, a pharmaceutical marketing executive with ...
Cached Medicine Technology:Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 3
(Date:6/30/2015)... ... June 30, 2015 , ... This Fourth of July, Peacock ... Alley story including hard work, tenacity, perseverance, commitment to quality, honesty and love of ... Born of Mary Ella Gabler's simple love of quilts, Peacock Alley was fully realized ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
(Date:6/29/2015)... ... 29, 2015 , ... The Society for Immunotherapy of Cancer ... granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic ... of nivolumab for patients with metastatic melanoma in Europe represents a major advance ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), announced ... (NDA) to the U.S. Food and Drug Administration ... approval for Xibrom QD,as a treatment for inflammation, ... ophthalmic solution), Xibrom is a topical non-steroidal ...
... Will Fund 20 Percent of Cost for New Hospital, ... that it has reached its $50 million Capital Campaign,goal, ... ever,undertaken. A recent gift of $500,000 from the Stephen ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
... 20 Today URAC called for,comments on ... Health Web,Site, HIPAA Privacy (Business Associate and ... Covered Entity) accreditation programs.,URAC is seeking input ... care management organizations and health plans. The,deadline ...
... MCG Capital,Corporation (Nasdaq: MCGC ) today announced ... the acquisition of Gould & Lamb, LLC by ABRY,Partners ... company that is unique to,the workers, compensation industry. The ... workers, compensation industry,since 2001. Having completed in excess of ...
... ... Nataline Sarkisyan ... GLENDALE, Calif., Dec. 20 In a stunning turn around,insurance ... California Nurses Association/National Nurses Organizing Committee,helped to generate, and agreed ...
... of Howard G. Smith,announces a September 4, 2007, ... in,the securities class action lawsuit filed on behalf ... Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or the "Company")(Nasdaq: THLD ... (the "Class Period"), including purchasers in Threshold,s,February 4, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2Health News:CIGNA Capitulates to Patient Revolt 2Health News:CIGNA Capitulates to Patient Revolt 3Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: